Drug Discovery World

FEBRUARY 8, 2024

Andrea O’Hara, PhD, Strategic Technical Specialist, Azenta Life Sciences led the presentation and was joined by Elizabeth Louie, PhD, Supervisor, Technical Applications, Xiangying Mao, PhD, Team Lead, Bioinformatics, and Crystal Richardson, PhD, Business Partnership Manager – all Azenta Life Sciences – for the questions section.

Gene Therapy 59

Gene Therapy Gene Bioinformatics Life Science 59

Drug Discovery World

OCTOBER 3, 2023

Andrea O’Hara, PhD, Strategic Technical Specialist, Azenta Life Sciences led the presentation and was joined by Elizabeth Louie, PhD, Supervisor, Technical Applications, Xiangying Mao, PhD, Team Lead, Bioinformatics, and Crystal Richardson, PhD, Business Partnership Manager – all Azenta Life Sciences – for the questions section.

Gene Therapy 52

Gene Therapy Gene Life Science Bioinformatics 52

XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. However, Dr. Bahassi reported that the selection of CTCs using this method is often not very efficient and the CTC population is usually highly contaminated with leukocytes. Detection of Genomic Alterations from cfDNA: Targeted, Non-Personalized Approaches.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98